Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CNTB
stocks logo

CNTB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.540
sliders
Low
7.00
Averages
8.50
High
10.00
Current: 2.540
sliders
Low
7.00
Averages
8.50
High
10.00
BTIG
Buy
initiated
$10
2025-10-31
Reason
BTIG
Price Target
$10
2025-10-31
initiated
Buy
Reason
BTIG initiated coverage of Connect Biopharma with a Buy rating and $10 price target. The firm believes rademikibart is "set up to thrive" in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.
Northland
Outperform
initiated
$7.50
2025-07-22
Reason
Northland
Price Target
$7.50
2025-07-22
initiated
Outperform
Reason
Northland initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target.
Northland
Carl Byrnes
Outperform
initiated
$7.50
2025-07-22
Reason
Northland
Carl Byrnes
Price Target
$7.50
2025-07-22
initiated
Outperform
Reason
As previously reported, Northland analyst Carl Byrnes initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target. Lead candidate rademikibart is positioned as the first biologic for treating acute exacerbations in asthma and COPD, addressing "a major unmet need" and "poised to define a new therapeutic category," the analyst tells investors. Topline data from its Phase 2 studies is expected in the first half of 2026, notes the analyst, who sees peak sales potential exceeding $5B.
H.C. Wainwright
Brandon Folkes
initiated
$7
2025-06-12
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$7
2025-06-12
initiated
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$8
2025-04-01
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$8
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$8
2025-03-31
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$8
2025-03-31
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB.O) is -1.98, compared to its 5-year average forward P/E of -3.51. For a more detailed relative valuation and DCF analysis to assess Connect Biopharma Holdings Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.51
Current PE
-1.98
Overvalued PE
-0.24
Undervalued PE
-6.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.11
Undervalued EV/EBITDA
-9.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1346.66
Current PS
0.00
Overvalued PS
8378.29
Undervalued PS
-5684.97
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CNTB News & Events

Events Timeline

(ET)
2025-12-01
08:50:00
Lake Street Initiates Buy Rating on Connect Biopharma with $9 Price Target
select
2025-11-12 (ET)
2025-11-12
09:03:11
Connect Biopharma Announces Q3 Earnings Per Share of 31 Cents, Exceeding Consensus Estimate of 24 Cents
select
2025-09-29 (ET)
2025-09-29
09:15:22
Connect Biopharma showcases rademikibart data at ERS Congress
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-13Benzinga
BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for market success.

  • Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.

[object Object]
Preview
9.5
11-12Newsfilter
Connect Biopharma Announces Financial Results for Q3 2025 and Offers Business Update

  • Clinical Trials Update: Connect Biopharma is actively recruiting participants for its Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD, with topline data expected in the first half of 2026.

  • Regulatory Progress: Simcere, Connect's exclusive licensee in Greater China, has submitted a New Drug Application for rademikibart for atopic dermatitis, which has been accepted by China's NMPA.

  • Corporate Developments: The company has terminated its American Depositary Receipt program and directly listed its ordinary shares on Nasdaq to enhance visibility and reduce costs.

  • Financial Overview: Connect Biopharma reported a net loss of $17.2 million for Q3 2025, with cash reserves expected to support operations into 2027, while also noting increased R&D expenses related to ongoing clinical trials.

[object Object]
Preview
4.0
10-31Benzinga
Immuneering Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday

  • Analyst Ratings Overview: Top Wall Street analysts have recently updated their ratings on several companies, including upgrades, downgrades, and new initiations.

  • Korro Bio, Inc.: Clear Street analyst Bill Maughan initiated coverage with a Buy rating and a price target of $93, while the stock closed at $36.45.

  • THOR Industries, Inc.: Loop Capital analyst Brandon Rolle initiated coverage with a Hold rating and a price target of $110, with shares closing at $103.35.

  • Connect Biopharma Holdings Limited: BTIG analyst Julian Harrison initiated coverage with a Buy rating and a price target of $10, despite the stock closing at $1.55.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Connect Biopharma Holdings Ltd (CNTB) stock price today?

The current price of CNTB is 2.54 USD — it has decreased -4.15 % in the last trading day.

arrow icon

What is Connect Biopharma Holdings Ltd (CNTB)'s business?

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

arrow icon

What is the price predicton of CNTB Stock?

Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Connect Biopharma Holdings Ltd (CNTB)'s revenue for the last quarter?

Connect Biopharma Holdings Ltd revenue for the last quarter amounts to 16.00K USD, decreased -98.69 % YoY.

arrow icon

What is Connect Biopharma Holdings Ltd (CNTB)'s earnings per share (EPS) for the last quarter?

Connect Biopharma Holdings Ltd. EPS for the last quarter amounts to -0.31 USD, increased 34.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Connect Biopharma Holdings Ltd (CNTB)'s fundamentals?

The market is revising Upward the revenue expectations for Connect Biopharma Holdings Limited (CNTB) for FY2025, with the revenue forecasts being adjusted by 179.06% over the past three months. During the same period, the stock price has changed by 45.14%.
arrow icon

How many employees does Connect Biopharma Holdings Ltd (CNTB). have?

Connect Biopharma Holdings Ltd (CNTB) has 62 emplpoyees as of December 05 2025.

arrow icon

What is Connect Biopharma Holdings Ltd (CNTB) market cap?

Today CNTB has the market capitalization of 141.99M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free